India’s pharma exports to cross $30 billion by year-end: Dr Jitendra Singh

THEBUSINESSBYTES BUREAU

NEW DELHI, SEPTEMBER 30, 2025

India’s pharmaceutical exports, currently valued at nearly $27.8 billion, are poised to cross the $30 billion mark by the end of this year, Union Minister of State (Independent Charge) for Science and Technology, Earth Sciences, Dr. Jitendra Singh said on Tuesday.

Speaking at the signing of a landmark Memorandum of Understanding (MoU) between the Department of Biotechnology (DBT) and the Government of Uttar Pradesh, Dr. Singh revealed that India’s domestic pharma market, pegged at $60 billion, is projected to more than double and touch $130 billion by 2030. The agreement, facilitated through DBT’s Biotechnology Industry Research Assistance Council (BIRAC) and the Uttar Pradesh Promote Pharma Council (UPPPC), is part of a centre–state partnership aimed at boosting innovation, entrepreneurship, and investment in pharma, biotech, and MedTech.

Highlighting the momentum in India’s MedTech sector, Dr. Singh said there are nearly 800 medical device manufacturers in the country, with the sector growing at an annual rate of 15–20 percent. He further underscored the rapid evolution of India’s biotech landscape, which has expanded from just 50 startups in 2014 to more than 11,000 today, cementing India’s global reputation as a vaccine hub that supplies over 60 percent of the world’s vaccines to more than 200 countries.

The Minister attributed this growth to robust policy support and a whole-of-government approach, adding that partnerships like the DBT–UP agreement would accelerate the vision of *Viksit Bharat 2047* and strengthen India’s role as a provider of affordable, world-class healthcare solutions.

DBT Secretary and BIRAC Chairman Dr. Rajesh S. Gokhale said the collaboration would “unlock innovation pipelines and scale up affordable technologies,” while state officials stressed Uttar Pradesh’s ambition to become a hub for pharma, biotech, and MedTech. Key initiatives such as the Biotech Park in Lucknow, the Medical Device Park in Greater Noida, and the Bulk Drug & Pharma Park in Lalitpur are expected to gain further traction under the partnership.

With India’s bioeconomy already valued at $165 billion, the Centre sees such state-level collaborations as vital to positioning the country as a global leader in accessible and affordable biopharma and MedTech.